Cresco Labs says rescheduling medical cannabis ‘a long-overdue step’

Cresco Labs (CRLBF) CEO Charlie Bachtell issued this statement in response to the Department of Justice’s final rule publication rescheduling medical cannabis from Schedule I to Schedule III under the Controlled Substances Act: “Rescheduling medical cannabis is a long-overdue step that finally brings federal policy closer to the science. For the first time in history, our federal government is classifying cannabis as medicine, validating the experiences of millions of patients who rely on it to help manage serious conditions and live better lives. This decision opens the door to expanded research, better data, more informed care, and broader access for those who need it most. It is a win for all patients nationwide and will usher in a new era of healthcare, where cannabis is treated like any other medicine. Cresco Labs commends President Trump and the administration for following through on bringing a commonsense approach to cannabis regulation.”